The Evolution of Risk Classification for Neuroblastoma
- PMID: 30754710
- PMCID: PMC6406722
- DOI: 10.3390/children6020027
The Evolution of Risk Classification for Neuroblastoma
Abstract
Neuroblastoma is a tumor with great clinical heterogeneity. Patients in North America are risk-stratified using a number of features including age at diagnosis, disease stage, tumor histology, MYCN status (amplified versus nonamplified), and tumor cell ploidy. In this paper, we review the evidence for utilizing these features in the risk classification of neuroblastic tumors. Additionally, we review the clinical and biologic criteria used by various cooperative groups to define low, intermediate, and high-risk disease populations in clinical trials, highlighting the differences in risk classification internationally. Finally, we discuss the development of the International Neuroblastoma Risk Group classification system, designed to begin worldwide standardization of neuroblastoma pretreatment risk classification and allow comparison of clinical trials conducted through different cooperative groups.
Keywords: neuroblastoma; risk classification.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures


Similar articles
-
Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.Cancer. 2001 Nov 15;92(10):2699-708. doi: 10.1002/1097-0142(20011115)92:10<2699::aid-cncr1624>3.0.co;2-a. Cancer. 2001. PMID: 11745206
-
TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.Cancer. 2004 Oct 15;101(8):1873-81. doi: 10.1002/cncr.20557. Cancer. 2004. PMID: 15386308
-
Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.J Clin Oncol. 2005 Dec 1;23(34):8819-27. doi: 10.1200/JCO.2004.00.2931. J Clin Oncol. 2005. PMID: 16314642 Clinical Trial.
-
Risk-based management: current concepts of treating malignant solid tumors of childhood.J Am Coll Surg. 1999 Oct;189(4):407-25. doi: 10.1016/s1072-7515(99)00167-2. J Am Coll Surg. 1999. PMID: 10509467 Review.
-
Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.Pathol Int. 2021 Apr;71(4):232-244. doi: 10.1111/pin.13085. Epub 2021 Mar 3. Pathol Int. 2021. PMID: 33657257 Review.
Cited by
-
Comparative epigenomics by machine learning approach for neuroblastoma.BMC Genomics. 2022 Dec 27;23(1):852. doi: 10.1186/s12864-022-09061-y. BMC Genomics. 2022. PMID: 36572864 Free PMC article.
-
Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome.Nat Genet. 2023 Apr;55(4):619-630. doi: 10.1038/s41588-023-01332-y. Epub 2023 Mar 27. Nat Genet. 2023. PMID: 36973454 Free PMC article.
-
Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions.Front Cell Dev Biol. 2024 Mar 27;12:1353860. doi: 10.3389/fcell.2024.1353860. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38601081 Free PMC article. Review.
-
"Re-educating" Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma.Front Immunol. 2020 Sep 2;11:1947. doi: 10.3389/fimmu.2020.01947. eCollection 2020. Front Immunol. 2020. PMID: 32983125 Free PMC article. Review.
-
Adult Patient With Neuroblastoma Presenting as Acute Leukemia.Cureus. 2022 Aug 8;14(8):e27769. doi: 10.7759/cureus.27769. eCollection 2022 Aug. Cureus. 2022. PMID: 36106239 Free PMC article.
References
-
- Pinto N.R., Applebaum M.A., Volchenboum S.L., Matthay M.M., London W.B., Ambros F.P., Nakagawara A., Berhold F., Schleirmacher G., Park J.R., et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J. Clin. Oncol. 2015;33:3008–3017. doi: 10.1200/JCO.2014.59.4648. - DOI - PMC - PubMed
-
- Cohn S.L., Pearson A.D., London W.B., Moniclar T., Amros P.F., Brodeur G.M., Faldum A., Hero B., Iheara T., Machin D., et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J. Clin. Oncol. 2009;27:289–297. doi: 10.1200/JCO.2008.16.6785. - DOI - PMC - PubMed
-
- Breslow N., McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res. 1971;31:2098–2103. - PubMed
Publication types
LinkOut - more resources
Full Text Sources